Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9

RG7652 is a fully humanized monoclonal antibody targeting human PCSK9, a regulator of serum low density lipoprotein cholesterol (LDLc) levels. RG7652 prevents degradation of the hepatic LDLc receptors by blocking PCSK9 binding and thereby resulting in efficient LDLc uptake by hepatocytes. The pharma...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :AAPS J
Главные авторы: Budha, Nageshwar R., Leabman, Maya, Jin, Jin Y., Wada, D. Russell, Baruch, Amos, Peng, Kun, Tingley, Whittemore G., Davis, John D.
Формат: Artigo
Язык:Inglês
Опубликовано: Springer US 2015
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4476990/
https://ncbi.nlm.nih.gov/pubmed/25823668
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1208/s12248-015-9750-8
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы